• In late February 2026, Globus Medical reported record Q4 2025 and full-year 2025 results, with sales rising to US$826.42 million for the quarter and US$2.94 billion for the year, and net income increasing to US$140.59 million and US$537.87 million respectively.
• Management reaffirmed 2026 revenue guidance of US$3.18 billion to US$3.22 billion while lifting non-GAAP EPS expectations and highlighting faster-than-planned benefits from the Nevro acquisition, underscoring how recent M&A and product innovation are shaping the company’s earnings profile.
• With this backdrop of record earnings and raised non-GAAP EPS guidance, we’ll examine how these results reshape Globus Medical’s existing investment narrative.

Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution.

Globus Medical Investment Narrative Recap

To own Globus Medical, you need to believe that its spine, trauma, and enabling technologies portfolio can compound value through innovation and well-executed M&A. The key near term catalyst is continued margin expansion as NuVasive and Nevro integration benefits flow through, while the biggest risk remains execution and integration complexity across these large deals. The latest record Q4 and full year 2025 results, plus raised non GAAP EPS guidance, generally support this thesis rather than materially changing it.

Among recent announcements, management’s reaffirmed 2026 revenue guidance of US$3.18 billion to US$3.22 billion, combined with higher non GAAP EPS expectations, is most relevant. It anchors the earnings acceleration story that many investors focus on as the main catalyst, especially with Nevro becoming accretive faster than initially outlined. At the same time, it intensifies attention on whether Globus can sustain margin gains while continuing to spend on R&D, enabling technologies and tuck in M&A.

But against this strong headline growth, investors should still be aware of the risk that extended sales cycles and competitive pressure in enabling technologies could...

Globus Medical's narrative projects $3.4 billion revenue and $538.8 million earnings by 2028.

Uncover how Globus Medical's forecasts yield a $106.40 fair value, a 11% upside to its current price.

Exploring Other Perspectives

The most cautious analysts were assuming only about US$3.4 billion of revenue and US$462 million of earnings by 2028, highlighting how differently you might view integration and competitive risks compared with the stronger Q4 2025 print.

Explore 5 other fair value estimates on Globus Medical - why the stock might be worth as much as 15% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Globus Medical research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Globus Medical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Globus Medical's overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 46 companies with promising cash flow potential yet trading below their fair value.
• This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.